oasis semaglutide Low Dose Oral for Overweight Adults (OASIS-4) | NEJM OASIS 2 Trial: Oral Semaglutide

What happened in the first clinical trial

Zhou Y, Tao L, Zhou X et al (2021) DHODH and cancer: promising prospects to be explored

Clinical monitoring and patient safety advice includes: Gastrointestinal symptoms : Patients should report severe or persistent nausea, vomiting, or abdominal pain, which may indicate pancreatitis (a warning in tirzepatide labeling) or require dose adjustment

doi: 10.1146/annurev-med-060513-093205 22 CampbellE

Furthermore, following the treatment of RGC-5 cells with IAA, there was an elevation in the levels of cysteinyl aspartate specific proteinase-3 (Caspase-3) and Caspase-7 proteins (Ondricek et al., 2012